Sacra estimates that Prosper Health surpassed $70M in annualized revenue in August 2026, up from an estimated $33M at the end of 2025.

Growth came from increased clinician capacity, paid-social spending that grew more than tenfold during 2025, broader state coverage, and deeper insurance relationships. Prosper's website says it has served 30,000 clients to date, and the company now describes itself as offering four products, adding revenue streams beyond its original assessment and therapy core.

Prosper Health has not publicly disclosed details of its fundraising rounds, including round sizes, lead investors, or valuations.

Prosper Health provides virtual healthcare for autistic and neurodivergent adults. Clients seeking an autism diagnosis complete intake forms and screening questionnaires before meeting with a licensed psychologist over video for a structured evaluation and formal diagnostic report.

Clients with an existing or new diagnosis can receive ongoing autism-focused therapy from licensed therapists over video. Prosper trains its clinicians in neurodiversity-affirming care for autistic adults rather than generalist therapy frameworks.

The platform checks insurance eligibility before booking, manages scheduling, processes claims, collects payments, and coordinates the clinician workforce. Clients use a consumer health app to find providers, book sessions, and manage care.

Prosper now describes itself as having four products, compared with its original assessment and therapy offerings. The company has not publicly detailed the newer products, which appear to cover adjacent services for neurodivergent adults.

Prosper uses W-2 and contract clinicians credentialed across multiple states. It had about 100 clinicians and 1,500 active clients in October 2024, grew past 200 clinicians by 2025, listed at least 400 in 2026 corporate descriptions, and may now approach 800 based on workforce-planning materials.

Prosper Health is a vertically integrated virtual care provider that sells directly to consumers through a B2C model. It acquires patients, matches them with clinicians, delivers care, and manages the revenue cycle, from insurance eligibility verification through claims submission and collections.

Most revenue comes from commercial health insurance. Prosper is in-network with Aetna, Blue Cross Blue Shield, Cigna, Oscar, Oxford, UnitedHealthcare, and other plans. Clients without suitable coverage can self-pay at $125 per therapy session or $950 for a comprehensive diagnostic assessment. Insurance expands Prosper's addressable market beyond cash-pay patients, who account for about 6.7% of U.S. mental-health patients.

Clinician compensation, credentialing, and claims administration account for most costs. Gross margins in insurance-enabled therapy businesses typically range from 20% to 45%, depending on payer mix, reimbursement rates, and clinician utilization. Prosper's paid-social acquisition costs are substantial and growing, but the company can amortize that spending across multiple visits per client.

Assessments provide a top-of-funnel entry point for recurring therapy revenue, as clients who receive a diagnosis may continue with regular sessions. Prosper is working to increase assessment-to-therapy conversion, therapy retention, reactivation of lapsed clients, and cross-selling across its product suite. Each incremental therapy session from an existing client carries no new acquisition cost.

Prosper Health competes with specialized neurodivergent care providers, generalist therapy platforms, and insurance-enabled clinician marketplaces. As a vertically focused virtual provider for autistic adults, it overlaps with several competitive categories.

BetterHelp generated about $1.03B in 2024 revenue, down 8.75% year over year, while Talkspace generated $187.6M, up 25%, with roughly 45% gross margins. Both platforms provide broad therapy access but lack autism-specific clinical protocols, specialized clinician training, and formal diagnostic pathways.

Prosper differentiates through specialization. Its matching process focuses on condition-specific expertise for autistic adults seeking diagnosis or neurodiversity-affirming therapy, rather than availability and general modality.

Rula reached approximately $470M in 2024 annualized gross revenue, up 100% year over year. It connects therapists with insured clients, manages credentialing and billing, and takes roughly 25% of therapist revenue. Headway, Alma, Grow Therapy, and SonderMind use similar models.

These platforms compete with Prosper for insured therapy visits but operate as horizontal marketplaces rather than condition-specific care providers. Prosper employs or contracts its own clinicians and controls the clinical experience end to end, allowing it to set training standards and develop proprietary assessment workflows while bearing the full cost of clinician capacity.

LifeStance generated $1.25B in 2024 revenue with 33% gross margins through a large network of in-person and virtual behavioral health providers. Local clinicians and regional practices also compete for the same patients, though long wait times and limited autism expertise in general practice create the access gap Prosper targets.

AI coaching products such as Sonia and Slingshot AI are adjacent offerings but not direct substitutes for licensed diagnosis. Administrative tools such as Camber and Orchid reduce the operational burden for independent clinicians, potentially enabling more solo practitioners to provide autism-focused care without joining Prosper.

Prosper Health operates in adult autism assessment and therapy. Its expansion vectors include adding service lines, deepening insurance and employer relationships, and scaling its clinical workforce across more states.

Prosper now describes itself as having four products, up from its original two pillars of diagnostic assessment and therapy. The newer offerings have not been publicly detailed, but adjacent needs among neurodivergent adults include ADHD evaluation, occupational support, medication management, and group-based programs.

Delivering new services to existing clients could increase lifetime value without incremental acquisition costs. Prosper is already working on cross-selling, while a broader product suite could strengthen its case for payer contracts as a multi-service neurodivergent care provider.

Prosper's current model is primarily direct-to-consumer with insurance billing. The company could also contract directly with health plans and self-insured employers as a specialized behavioral health benefit, creating a B2B2C channel.

As employers add mental health and neurodiversity support to benefits packages, Prosper could pitch benefits buyers on shorter wait times, diagnostic accuracy, and therapy retention. The opportunity could expand as awareness of adult autism grows and more employees seek formal evaluation.

Prosper's clinician base has grown from roughly 100 in late 2024 to potentially around 800 based on current workforce-planning materials. Each additional state where Prosper credentials providers opens a geographic market, while telehealth regulations loosened during COVID have largely remained favorable.

Clinician supply is the binding constraint on growth. Diagnostic assessments require licensed psychologists, and therapy caseloads limit how many clients each therapist can serve. Prosper's expansion depends on its ability to recruit, train, and retain autism-specialized clinicians at scale. AI tools for intake, clinical documentation, and billing can improve clinician productivity at the margins, but licensed providers remain necessary for the core service.

Clinician supply constraints: Prosper's revenue scales linearly with the number of licensed psychologists and therapists it can recruit, credential, and retain, while the specialized nature of autism-focused care narrows the available talent pool relative to generalist platforms and could constrain growth if clinician acquisition does not keep pace with patient demand.

Reimbursement and payer risk: Most of Prosper's revenue depends on commercial insurance reimbursement rates set by payers and subject to change, so tighter coverage criteria for adult autism assessments, lower per-session rates, or higher claims denial rates could compress margins or slow growth.

Acquisition cost sustainability: Prosper's paid-social budget grew more than tenfold during 2025 to acquire patients, and if customer acquisition costs rise faster than lifetime value from assessment-to-therapy conversion and retention, the company could face margin pressure that is difficult to offset without raising prices or shifting to lower-cost acquisition channels.